Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
暂无分享,去创建一个
S. Harper | N. Gennari | V. Summa | G. Paonessa | J. Ontoria | A. Di Marco | F. Ferrigno | M. Kaiser | I. Biancofiore | A. Bresciani | Savina Malancona | R. Graziani | Simona Ponzi
[1] David Horn,et al. Melarsoprol Resistance in African Trypanosomiasis. , 2018, Trends in parasitology.
[2] D. Tshala-Katumbay,et al. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo , 2018, PLoS neglected tropical diseases.
[3] Giuliano Cecchi,et al. Human African trypanosomiasis , 2017, The Lancet.
[4] Ian H. Gilbert,et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need , 2017, Nature Reviews Microbiology.
[5] Jessica A. Engel,et al. Design and Synthesis of Novel Anti‐Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit , 2017, Archiv der Pharmazie.
[6] A. Mai,et al. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. , 2017, Journal of medicinal chemistry.
[7] V. Lather,et al. Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis. , 2016, Current topics in medicinal chemistry.
[8] S. Harper,et al. Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs. , 2016, ACS medicinal chemistry letters.
[9] F. Chappuis,et al. Treatment options for second-stage gambiense human African trypanosomiasis , 2014, Expert review of anti-infective therapy.
[10] Ana Rodriguez,et al. Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. , 2014, MedChemComm.
[11] A. Holmgren,et al. Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei * , 2013, The Journal of Biological Chemistry.
[12] I. Gilbert,et al. From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules , 2013, ChemMedChem.
[13] Michel Quere,et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] E. Fèvre,et al. Estimating and Mapping the Population at Risk of Sleeping Sickness , 2012, PLoS neglected tropical diseases.
[15] C. Burri,et al. Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness , 2012, PLoS neglected tropical diseases.
[16] Michael J. Zdilla,et al. Enantioselective synthesis of cocaine C-1 analogues using sulfinimines (N-sulfinyl imines). , 2012, The Journal of organic chemistry.
[17] L. Scapozza,et al. Crystal Structures of T. b. rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation , 2011, PLoS neglected tropical diseases.
[18] M. Phillips,et al. State of the art in African trypanosome drug discovery. , 2011, Current topics in medicinal chemistry.
[19] F. A. Davis,et al. Asymmetric synthesis of substituted homotropinones from N-sulfinyl beta-amino ketone ketals. (-)-Euphococcinine and (-)-adaline. , 2010, Organic letters.
[20] Stuart P. McElroy,et al. Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei , 2009, ChemMedChem.
[21] M. Rowley,et al. Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[22] L. Scapozza,et al. Adenosine Kinase of T. b. rhodesiense Identified as the Putative Target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Using Chemical Proteomics , 2009, PLoS neglected tropical diseases.
[23] Salah Ghabri,et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.
[24] M. Rowley,et al. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. , 2009, Journal of medicinal chemistry.
[25] Timothy N C Wells,et al. Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy , 2008, Antimicrobial Agents and Chemotherapy.
[26] R. De Francesco,et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. , 2008, Journal of medicinal chemistry.
[27] G. Cross,et al. Acetylation of histone H4K4 is cell cycle regulated and mediated by HAT3 in Trypanosoma brucei , 2007, Molecular microbiology.
[28] G. Priotto,et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] B. Mpia,et al. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[30] Ching C. Wang,et al. An Aurora Kinase Homologue Is Involved in Regulating Both Mitosis and Cytokinesis in Trypanosoma brucei* , 2006, Journal of Biological Chemistry.